SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-193621"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-193621" > Rituximab Maintenan...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003655naa a2200481 4500
001oai:DiVA.org:uu-193621
003SwePub
008130205s2012 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-1936212 URI
0247 a https://doi.org/10.1200/JCO.2012.41.94162 DOI
040 a (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Gisselbrecht, Christian4 aut
2451 0a Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20(+) Diffuse Large B-Cell Lymphoma :b Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma
264 1c 2012
338 a print2 rdacarrier
520 a Purpose The standard treatment for relapsed diffuse large B-cell lymphoma (DLBCL) is salvage chemotherapy followed by high-dose therapy and autologous stem-cell transplantation (ASCT). The impact of maintenance rituximab after ASCT is not known. Patients and Methods In total, 477 patients with CD20(+) DLBCL who were in their first relapse or refractory to initial therapy were randomly assigned to one of two salvage regimens. After three cycles of salvage chemotherapy, the responding patients received high-dose chemotherapy followed by ASCT. Then, 242 patients were randomly assigned to either rituximab every 2 months for 1 year or observation. Results After ASCT, 122 patients received rituximab, and 120 patients were observed only. The median follow-up time was 44 months. The 4-year event-free survival (EFS) rates after ASCT were 52% and 53% for the rituximab and observation groups, respectively (P=.7). Treatment with rituximab was associated with a 15% attributable risk of serious adverse events after day 100, with more deaths (six deaths v three deaths in the observation arm). Several factors affected EFS after ASCT (P<.05), including relapsed disease within 12 months (EFS: 46% v 56% for relapsed disease after 12 months), secondary age-adjusted International Prognostic Index (saaIPI) more than 1 (EFS: 37% v 61% for saaIPI < 1), and prior treatment with rituximab (EFS: 47% v 59% for no prior rituximab). A significant difference in EFS between women (63%) and men (46%) was also observed in the rituximab group. In the Cox model for maintenance, the saaIPI was a significant prognostic factor (P<.001), as was male sex (P=.01). Conclusion In relapsed DLBCL, we observed no difference between the control group and the rituximab maintenance group and do not recommend rituximab after ASCT.
7001 a Schmitz, Norbert4 aut
7001 a Mounier, Nicolas4 aut
7001 a Gill, Devinder Singh4 aut
7001 a Linch, David C.4 aut
7001 a Trneny, Marek4 aut
7001 a Bosly, Andre4 aut
7001 a Milpied, Noel J.4 aut
7001 a Radford, John4 aut
7001 a Ketterer, Nicolas4 aut
7001 a Shpilberg, Ofer4 aut
7001 a Duehrsen, Ulrich4 aut
7001 a Hagberg, Hansu Uppsala universitet,Enheten för onkologi4 aut0 (Swepub:uu)hanshagb
7001 a Ma, David D.4 aut
7001 a Viardot, Andreas4 aut
7001 a Lowenthal, Ray4 aut
7001 a Briere, Josette4 aut
7001 a Salles, Gilles4 aut
7001 a Moskowitz, Craig H.4 aut
7001 a Glass, Bertram4 aut
7102 a Uppsala universitetb Enheten för onkologi4 org
7730 t Journal of Clinical Oncologyg 30:36, s. 4462-4469q 30:36<4462-4469x 0732-183Xx 1527-7755
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-193621
8564 8u https://doi.org/10.1200/JCO.2012.41.9416

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy